Untitled

Abstract

Present data suggest a potential role of circulating CgA in the management of prostate cancer patients. CgA determination may be useful diagnostically and prognostically and could offer complementary information with respect to PSA. Serial evaluation of circulating CgA could provide information on changes in the NE phenotype expression as a consequence of tumor progression and/or treatment administration.

Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy

“…The significant association between elevated CgA levels and the other parameters related to the aggressiveness of the tumor should suggest that CgA measurement may preoperatively predict the risk of progression in this kind of population. Recently, Berruti et al (2005), in a longitudinal analysis on metastatic prostate cancers, showed that CgA-elevated levels are significantly associated to the risk of progression and to survival. We showed that also in a population of non-metastatic prostate adenocarcinomas submitted to RRP, CgA measurement could significantly predict the risk of biochemical (PSA) progression after surgery.…”

“…It has been suggested that prostate adenocarcinoma presenting high levels of markers of NE differentiation tend to be more aggressive (Abrahamsson et al 1989, Sciarra et al 2003, Berruti et al 2005, Taplin et al 2005. More convincing data have been reported in the advanced and hormonerefractory stage of the tumor, where NE activity is highly increased (Cohen et al 1991, Berruti et al 2005, Taplin et al 2005. Some authors, using a multivariate analysis, sustained that also in non-metastatic prostate cancer, NE differentiation and CgA can be associated with the aggressiveness of the tumor (Weinstein et al 1996, Ahlegren et al 2000, Sciarra et al 2004.…”

“…In patients with prostate cancer, circulating CgA has been found to reflect the immunohistochemical (Abrahamsson et al 1989) and RT-PCR findings (Sciarra et al 2003) at prostate cancer tissue level. It has been suggested that prostate adenocarcinoma presenting high levels of markers of NE differentiation tend to be more aggressive (Abrahamsson et al 1989, Sciarra et al 2003, Berruti et al 2005, Taplin et al 2005. More convincing data have been reported in the advanced and hormonerefractory stage of the tumor, where NE activity is highly increased (Cohen et al 1991, Berruti et al 2005, Taplin et al 2005.…”